Fuchs' endothelial corneal dystrophy for Greater Independence in Everyday Life

FECD shows up three to four times more frequently in women than in men and almost always involves both eyes. Most diagnoses appear in people aged 40 to 50, though the condition is not exclusive to that window — it can emerge significantly earlier or much later in life.

The progression tends to be gradual, and the degree of impact varies widely between individuals. Some people live with the condition and never experience meaningful vision disruption. Others notice troubling blurring and glare relatively soon after the condition begins.

In the majority of cases, FECD occurs sporadically, meaning there is no identifiable family history. However, it can also be inherited through an autosomal dominant pattern. If one of your parents carries the condition, you have roughly a 50 per cent likelihood of developing it yourself.

Because treatment is only necessary when vision problems arise, family members do not require special screening beyond standard routine eye examinations with a local optometrist. FECD is confined to the eye — it does not affect any other organ or body system.

At the heart of the condition lies the endothelium, a single cell layer lining the posterior aspect of the cornea. Its essential job is fluid regulation: constantly pumping surplus water out of the corneal stroma to preserve transparency. When this pump fails, fluid buildup obscures vision.

Excess corneal fluid scatters incoming light, which is why brightness often feels uncomfortable. Many people report increased glare, halos surrounding light sources, and difficulty seeing in intensely lit environments. These symptoms frequently intensify during nighttime driving.

Over time, the disease can produce characteristic deposits called guttata along the posterior cornea. These appear as tiny, irregular bump-like changes in the endothelial layer and are visible only through specialized microscopic equipment. Guttata disrupt the smooth passage of light, contributing further to glare and visual disturbance.

In the later stages, some individuals find that their vision no longer clears up as the day progresses. This happens because enough endothelial cells have been lost for fluid to remain trapped in the cornea permanently, keeping its layers persistently swollen rather than recovering overnight.

When the epithelium — the outermost corneal layer rich with nerve endings — becomes swollen, it can trigger a persistent gritty, painful sensation in the eyes.

Persistent corneal swelling can occasionally lead to the formation of surface blisters, referred to as epithelial bullae. This complication is known as bullous keratopathy. If one of these blisters ruptures, it can produce sudden, sharp pain alongside ongoing discomfort.

Despite these possibilities, the vast majority of people with FECD experience a very slow progression. It is entirely possible to go extended periods without any noticeable symptoms interfering with normal life.

When visual changes begin to interfere with everyday tasks, your ophthalmologist may discuss the option of a corneal transplant. Surgical intervention has proven effective in restoring clarity for many patients with advanced FECD.

A corneal transplant, medically termed keratoplasty or corneal grafting, involves replacing damaged corneal tissue with healthy donor tissue. Procedures can address the entire cornea or target only specific layers, depending on the nature and extent of the disease.

Your ophthalmologist will assess your individual case and determine the right timing for transplant consideration, explaining the risks and benefits tailored to your situation.

For FECD specifically, the standard surgical approach is endothelial keratoplasty — a selective transplant that replaces only the diseased innermost corneal layers rather than the whole thickness of the cornea, resulting in faster recovery and stronger structural integrity.